Tempus Launches Prospective “Priority” Research Study and Increases Support for Oncology Research Initiatives Despite Pandemic Challenges
01 juin 2020 10h18 HE
|
Tempus
CHICAGO, June 01, 2020 (GLOBE NEWSWIRE) -- Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, today announces its...
Rubius Therapeutics to Present Preclinical Data for RTX-321, a Red Cell Therapeutic™ Oncology Product Candidate for HPV-Positive Cancers at the American Association of Cancer Research Annual Meeting
15 mai 2020 08h00 HE
|
Rubius Therapeutics
CAMBRIDGE, Mass., May 15, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an...
Cybrexa Therapeutics to Present First Efficacy and Safety Data From Its Lead Program CBX-12 and Initial Data From CBX-13 at the American Association for Cancer Research (AACR) Virtual Annual Meeting II
15 mai 2020 04h00 HE
|
Cybrexa Therapeutics
NEW HAVEN, Conn., May 15, 2020 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, an oncology-focused biotechnology company developing a new class of therapeutics through its alphalex™ tumor targeting...
Rubius Therapeutics Highlights Preclinical Data for RTX-321, a Red Cell Therapeutic™ Oncology Product Candidate for HPV-Positive Cancers, at the American Society of Gene & Cell Therapy 23rd Annual Meeting
12 mai 2020 06h00 HE
|
Rubius Therapeutics
CAMBRIDGE, Mass., May 12, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an...
Rubius Therapeutics Announces Dosing of First Patient in Phase 1/2 Trial of RTX-240, an Allogeneic Cellular Therapy, for the Treatment of Solid Tumors
07 mai 2020 08h00 HE
|
Rubius Therapeutics
CAMBRIDGE, Mass., May 07, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an...
Rubius Therapeutics Announces Preclinical Data from Red Cell Therapeutic Oncology Programs to be Presented at the ASGCT 23rd Annual Meeting
29 avr. 2020 08h00 HE
|
Rubius Therapeutics
CAMBRIDGE, Mass., April 29, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an...
Cybrexa Therapeutics Announces Arthur DeCillis, MD as Acting Chief Medical Officer to Support CBX-12’s Entry into the Clinic
31 mars 2020 08h00 HE
|
Cybrexa Therapeutics
NEW HAVEN, Conn., March 31, 2020 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, an oncology-focused biotechnology company developing a new class of therapeutics through its alphalex™ tumor targeting...
MEI Pharma, Partnerships, Well-Funded Clinical Programs and Promising Clinical Data Driving Oncology Research
11 juin 2018 08h00 HE
|
Traders News Source LLC
NEW YORK, NY, June 11, 2018 (GLOBE NEWSWIRE) -- Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a...
OnCore Biopharma Announces Exclusive HBV Research Collaboration With the Baruch S. Blumberg Institute
19 nov. 2014 07h00 HE
|
OnCore Biopharma, Inc.
DOYLESTOWN, Pa., Nov. 19, 2014 (GLOBE NEWSWIRE) -- OnCore Biopharma, Inc. ("OnCore" or the "Company"), a biopharmaceutical company focused on the research, development and commercialization of oral...